“Stratifying hepatic meta-inflammation: consequences for cancer therapy”
Event details
| Date | 17.03.2022 |
| Hour | 12:15 › 13:30 |
| Speaker | Prof. Dr. Mathias HEIKENWÄLDER |
| Location | |
| Category | Conferences - Seminars |
| Event Language | English |
A Lola and John Grace Distinguished Lecture in Cancer Research
Mathias Heikenwälder - Department H, German Cancer Research Center (DKFZ) in Heidelberg, Germany.
Research interests: Microbiology, Cancer research, Chronic inflammation,Liver carcinogenesis, Immunotherapy, Preclinical mouse models
Mathias Heikenwälder is an Austrian microbiologist and cancer researcher working in the field of chronic inflammation and liver carcinogenesis.
chronic inflammation and liver carcinogenesis. He investigates the molecular mechanisms that cause chronic inflammation, tissue damage, cancer and metastasis. Prof. Heikenwälder is developing new models and therapeutic approaches in close cooperation with clinics.
The Heikenwälder laboratory aims at understanding the different immune signatures of chronic inflammatory human diseases using relevant mouse models - with the final aim to generate models of chronic inflammation potentially used for pre-clinical research. The Heikenwälder laboratory focuses on comparative studies of human and animal tissues, recapitulating human disease on a histo-pathological and pathophysiological level. The laboratory engages in classical molecular biology techniques complemented with sophisticated ways to receive as much information from tissue samples through histology (e.g. light microscopy/ immune fluorescence/ FISH/ in situ hybridization), other in vivo imaging techniques (e.g. MRI) as well as through FACS analyses for tissue homogenates. At the same time, the Heikenwälder laboratory is also interested in the systemic functional effects of pathologies and the interplay between several affected non-lymphoid tissues and the immune system.
Finally, testing several therapeutic compounds in a single use but also combinatorial fashion is one of the goals employing established and stratified pre-clinical mouse models.
Prof. Heikenwälder publishes his work in high-ranking journals and has established himself as an international leader in the field of liver cancer. Mathias Heikenwälder is the third most frequently cited German-speaking researcher in the field of cell biology in the last 5 years and was one of the Highly Cited Researchers (Cross Fields) (Web of Science Group) in 2019, 2020 and 2021. Not only have his publications been widely cited by the research community, but they have also shifted fatty liver and liver cancer research in new directions - relevant to the day-to-day management of patients with fatty liver or liver cancer. The current H-Factor of Mathias Heikenwälder is 75 (Web of Science), with 281 publications listed in Pubmed.
Mathias Heikenwälder - Department H, German Cancer Research Center (DKFZ) in Heidelberg, Germany.
Research interests: Microbiology, Cancer research, Chronic inflammation,Liver carcinogenesis, Immunotherapy, Preclinical mouse models
Mathias Heikenwälder is an Austrian microbiologist and cancer researcher working in the field of chronic inflammation and liver carcinogenesis.
chronic inflammation and liver carcinogenesis. He investigates the molecular mechanisms that cause chronic inflammation, tissue damage, cancer and metastasis. Prof. Heikenwälder is developing new models and therapeutic approaches in close cooperation with clinics.
The Heikenwälder laboratory aims at understanding the different immune signatures of chronic inflammatory human diseases using relevant mouse models - with the final aim to generate models of chronic inflammation potentially used for pre-clinical research. The Heikenwälder laboratory focuses on comparative studies of human and animal tissues, recapitulating human disease on a histo-pathological and pathophysiological level. The laboratory engages in classical molecular biology techniques complemented with sophisticated ways to receive as much information from tissue samples through histology (e.g. light microscopy/ immune fluorescence/ FISH/ in situ hybridization), other in vivo imaging techniques (e.g. MRI) as well as through FACS analyses for tissue homogenates. At the same time, the Heikenwälder laboratory is also interested in the systemic functional effects of pathologies and the interplay between several affected non-lymphoid tissues and the immune system.
Finally, testing several therapeutic compounds in a single use but also combinatorial fashion is one of the goals employing established and stratified pre-clinical mouse models.
Prof. Heikenwälder publishes his work in high-ranking journals and has established himself as an international leader in the field of liver cancer. Mathias Heikenwälder is the third most frequently cited German-speaking researcher in the field of cell biology in the last 5 years and was one of the Highly Cited Researchers (Cross Fields) (Web of Science Group) in 2019, 2020 and 2021. Not only have his publications been widely cited by the research community, but they have also shifted fatty liver and liver cancer research in new directions - relevant to the day-to-day management of patients with fatty liver or liver cancer. The current H-Factor of Mathias Heikenwälder is 75 (Web of Science), with 281 publications listed in Pubmed.
Practical information
- Informed public
- Free
- This event is internal
Organizer
- Prof. Freddy Radtke
Contact
- Lisa Smith, ISREC Administrative Assistant